Albany, NY – DelveInsight launched its new report on Soft Tissue Sarcoma Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s ‘Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Some of the key facts of the report:
1. Soft Tissue Sarcoma total incident population in seven major markets was 40,155 in 2017.2. Among all the seven major markets, the United States accounts for the highest number of Soft Tissue Sarcoma cases.3. There was a total of 9,925 male and 7,555 female diagnosed cases of Soft Tissue Sarcoma in 2017 in the United States.4. In the European countries, Germany had the highest Soft Tissue Sarcoma incident population with 4,781 cases, followed by Italy, which had an incident population of 4,082 in 2017.5. Among the 7MM, in 2017, the lowest Soft Tissue Sarcoma incident population were recorded in Spain.
Key benefits of the report:
1. Soft Tissue Sarcoma market report covers a descriptive overview and comprehensive insight of the Soft Tissue Sarcoma Epidemiology and Soft Tissue Sarcoma market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Soft Tissue Sarcoma market report provides insights on the current and emerging therapies.3. Soft Tissue Sarcoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Soft Tissue Sarcoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Soft Tissue Sarcoma market.
Request for sample pages: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market
“The total Soft Tissue Sarcoma market size, excluding Gastrointestinal stromal tumors (GIST) in seven major markets was USD 246.7 million in 2017.”
Soft Tissue Sarcoma has many histologic subtypes, and the malignancy can be low or high grade. Soft Tissue Sarcoma treatments may include surgery, chemotherapy, radiation therapy, or a combination of these therapies. The treatment outcome of locally advanced or locally relapsed disease by combining local treatment (surgery, radiotherapy) with systemic therapy, such as neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy.
The key players in Soft Tissue Sarcoma market are:1. Blueprint Medicines Corporation2. Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical3. Karyopharm Therapeutics4. Deciphera Pharmaceuticals5. Philogen6. GlaxoSmithKline7. Epizyme8. Eli Lilly and Company9. Pfizer10. Aadi Bioscience11. Sierra Oncology12. Nanobiotix13. Taiho Oncology14. Arog Pharmaceuticals15. Merck Sharp & DohmeAnd many others
Drugs covered1. Avapritinib (BLU-285)2. Anlotinib (AL3818)3. Selinexor4. Aldoxorubicin (INNO-206)5. Ripretinib (DCC-2618)6. Fibromun (In combination with Doxorubicin)7. Hensify (NBTXR3)8. Crenolanib9. TAS-11610. GSK337779411. ADP-A2M412. Tazemetostat (EPZ-6438)13. AMG 33714. GB226/APL-50115. CamsirubicinAnd many others
Request a free sample report @https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market
Table of contents1. Key Insights2. Executive Summary of Soft-Tissue Sarcoma3. Soft-Tissue Sarcomas Market Overview at a Glance4. Soft-Tissue Sarcoma Disease Background and Overview5. Soft-Tissue Sarcoma Epidemiology and Patient Population6. Case Reports7. Country Wise Soft-Tissue Sarcoma Epidemiology7.1. United States Epidemiology7.2. EU5 Epidemiology7.2.1. Germany7.2.2. France7.2.3. Italy7.2.4. Spain7.2.5. United Kingdom7.3. Japan Epidemiology8. Soft-Tissue Sarcoma Treatment and Management9. Unmet Needs10. Soft-Tissue Sarcoma Marketed Drugs10.1. Halaven (Eribulin Mesylate): Eisai10.2. Gleevec (Imatinib Mesylate): Novartis10.3. Yondelis (Trabectedin): Pharma Mar10.4. Lartruvo (Olaratumab): Eli Lilly10.5. Vitrakvi (Larotrectinib; BAY2757556): Bayer/Loxo Oncology10.6. Stivarga (Regorafenib): Bayer10.7. Sutent (Sunitinib malate): Pfizer10.8. Votrient (Pazopanib): GlaxoSmithKline/Novartis10.9. Vincristine Sulfate: Hospira10.10. Rozlytrek (Entrectinib): Roche (Genentech)11. Soft-Tissue Sarcoma Emerging Drugs11.1. Key Cross Competition- Phase III Emerging Molecules11.2. Avapritinib (BLU-285): Blueprint Medicines Corporation11.3. Vigil (In combination with irinotecan and temozolomide): Gradalis11.4. Anlotinib (AL3818): Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical11.5. Selinexor: Karyopharm Therapeutics11.6. Aldoxorubicin (INNO-206): CytRx11.7. Ripretinib (DCC-2618): Deciphera Pharmaceuticals11.8. Fibromun (In combination with Doxorubicin): Philogen11.9. Hensify (NBTXR3): Nanobiotix11.10. Crenolanib: Arog Pharmaceuticals11.11. TAS-116: Taiho Pharmaceutical11.12. GSK3377794: GlaxoSmithKline/ Adaptimmune11.13. ADP-A2M4: Adaptimmune12. Soft Tissue Sarcoma 7 Major Market Analysis13. Market Outlook: The United States13.1. United States Market Size14. Market Outlook: Europe14.1. Germany14.2. France14.3. Italy14.4. Spain14.5. United Kingdom15. Soft-Tissue Sarcoma Market Outlook: Japan16. Access and Reimbursement Overview of Soft-Tissue Sarcoma17. Market Drivers18. Market Barriers19. SWOT Analysis20. Appendix21. DelveInsight Capabilities22. Disclaimer23. About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Related reports:
Soft Tissue Sarcoma – Epidemiology Forecast to 2030
Soft Tissue Sarcoma Pipeline Insight, 2020
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NEVADA 89107Country: United StatesWebsite: https://www.delveinsight.com/